Skip to content


Journal for ImmunoTherapy of Cancer


Sort by
Previous Page Page 1 of 61 Next Page
  1. Content type: Research article

    Merkel Cell carcinoma (MCC) is a rare but aggressive cancer, with an estimated disease-associated mortality as high as 46%. MCC has proven to be an immunologically responsive disease and the advent of immune c...

    Authors: Isaac S. Chan, Shailender Bhatia, Howard L. Kaufman and Evan J. Lipson

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:23

    Published on:

  2. Content type: Case report

    Pembrolizumab is an anti–programmed death 1 (PD-1) receptor monoclonal antibody that has shown activity as second line treatment for metastatic head and neck squamous cell carcinoma (HNSCC). Immune-related advers...

    Authors: Fanny Zulay Acero Brand, Nicolas Suter, Jean-Philippe Adam, Bernard Faulques, Antonio Maietta, Denis Soulières and Normand Blais

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:22

    Published on:

  3. Content type: Research article

    Prostatic acid phosphatase (PAP) is a prostate tumor antigen, and the target of the only FDA-approved anti-tumor vaccine, sipuleucel-T. We have previously reported in two clinical trials that a DNA vaccine enc...

    Authors: Ellen Wargowski, Laura E. Johnson, Jens C. Eickhoff, Lauren Delmastro, Mary Jane Staab, Glenn Liu and Douglas G. McNeel

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:21

    Published on:

  4. Content type: Research article

    While immune checkpoint blockade has greatly improved clinical outcomes in diseases such as melanoma, there remains a need for predictive biomarkers to determine who will likely benefit most from which therapy...

    Authors: Priyanka B. Subrahmanyam, Zhiwan Dong, Daniel Gusenleitner, Anita Giobbie-Hurder, Mariano Severgnini, Jun Zhou, Michael Manos, Lauren M. Eastman, Holden T. Maecker and F. Stephen Hodi

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:18

    Published on:

  5. Content type: Research article

    Immuno-oncology and cancer immunotherapies are areas of intense research. The numbers and locations of CD8+ tumor-infiltrating lymphocytes (TILs) are important measures of the immune response to cancer with pr...

    Authors: Keith E. Steele, Tze Heng Tan, René Korn, Karma Dacosta, Charles Brown, Michael Kuziora, Johannes Zimmermann, Brian Laffin, Moritz Widmaier, Lorenz Rognoni, Ruben Cardenes, Katrin Schneider, Anmarie Boutrin, Philip Martin, Jiping Zha and Tobias Wiestler

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:20

    Published on:

  6. Content type: Research article

    Despite improved survival following checkpoint inhibitors, there is still a potential role for anti-cancer therapeutic vaccines. Because of biological heterogeneity and neoantigens resulting from each patient’...

    Authors: Robert O. Dillman, Andrew N. Cornforth, Gabriel I. Nistor, Edward F. McClay, Thomas T. Amatruda and Carol Depriest

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:19

    Published on:

  7. Content type: Research article

    BTH1677, a beta-glucan pathogen-associated molecular pattern molecule, drives an anti-cancer immune response in combination with oncology antibody therapies. This phase II study explored the efficacy, pharmaco...

    Authors: Walburga Engel-Riedel, Jamie Lowe, Paulette Mattson, J. Richard Trout, Richard D. Huhn, Michele Gargano, Myra L. Patchen, Richard Walsh, My My Trinh, Mariève Dupuis and Folker Schneller

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:16

    Published on:

  8. Content type: Research article

    Numerous oncology combination therapies involving modulators of the cancer immune cycle are being developed, yet quantitative simulation models predictive of outcome are lacking. We here present a model-based ...

    Authors: Yuri Kosinsky, Simon J. Dovedi, Kirill Peskov, Veronika Voronova, Lulu Chu, Helen Tomkinson, Nidal Al-Huniti, Donald R. Stanski and Gabriel Helmlinger

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:17

    Published on:

  9. Content type: Research article

    The impact of programmed death receptor-ligand1 (PD-L1) on costs and value of the immune check point inhibitors (ICPI) has received minimal attention. Objectives: 1- Design a sliding scale to grade survival in...

    Authors: Helmy M. Guirgis

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:15

    Published on:

  10. Content type: Case report

    Immune checkpoint therapy has dramatically changed the landscape of cancer therapy, providing an efficacious and durable therapeutic option for patients with advanced-stage disease. However, dermatologic toxic...

    Authors: Michael T. Tetzlaff, Kelly C. Nelson, Adi Diab, Gregg A. Staerkel, Priyadharsini Nagarajan, Carlos A. Torres-Cabala, Beth A. Chasen, Jennifer A. Wargo, Victor G. Prieto, Rodabe N. Amaria and Jonathan L. Curry

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:14

    Published on:

  11. Content type: Case report

    Uveal melanoma accounts for 85% of the ocular melanomas and has an increased risk of hematogenous spread, most commonly to the liver. After curative intent therapy like surgery and radiation, fifty percent of ...

    Authors: Muhammad Zubair Afzal, Rodwell Mabaera and Keisuke Shirai

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:13

    Published on:

  12. Content type: Case report

    Immune check point inhibitors (ICIs) have emerged as a new therapeutic paradigm for a variety of malignancies including metastatic melanoma. As the use of ICIs expand, immune-mediated adverse events are becomi...

    Authors: Amrita Padda, Elena Schiopu, Justin Sovich, Vincent Ma, Ajjai Alva and Leslie Fecher

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:12

    Published on:

  13. Content type: Research article

    Immuno-oncotherapy has emerged as a promising means to target cancer. In particular, therapeutic manipulation of tumor-associated macrophages holds promise due to their various and sometimes opposing roles in ...

    Authors: Grace Mahlbacher, Louis T. Curtis, John Lowengrub and Hermann B. Frieboes

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:10

    Published on:

  14. Content type: Case report

    Ipilimumab is an FDA-approved anti-CTLA-4 monoclonal antibody used in treatment of metastatic melanoma. We present an unusual neurological complication of Ipilimumab therapy and the diagnostic dilemma it caused.

    Authors: Lorraine Cafuir, David Lawson, Nilesh Desai, Vita Kesner and Alfredo Voloschin

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:11

    Published on:

  15. Content type: Meeting report

    Radiotherapy (RT) has been a fundamental component of the anti-cancer armamentarium for over a century. Approximately half of all cancer patients are treated with radiotherapy during their disease course. Over...

    Authors: Ariel E. Marciscano, Joshua M. Walker, Heather M. McGee, Michelle M. Kim, Charles A. Kunos, Arta M. Monjazeb, Stephen L. Shiao, Phuoc T. Tran and Mansoor M. Ahmed

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:6

    Published on:

  16. Content type: Research article

    Nivolumab is approved for patients with metastatic renal cell carcinoma (mRCC) refractory to prior antiangiogenic therapy. The clinical activity of nivolumab in patients with non-clear cell RCC subtypes remain...

    Authors: Vadim S. Koshkin, Pedro C. Barata, Tian Zhang, Daniel J. George, Michael B. Atkins, William J. Kelly, Nicholas J. Vogelzang, Sumanta K. Pal, JoAnn Hsu, Leonard J. Appleman, Moshe C. Ornstein, Timothy Gilligan, Petros Grivas, Jorge A. Garcia and Brian I. Rini

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:9

    Published on:

  17. Content type: Review

    Immune checkpoint inhibitors targeting the PD-1 pathway have greatly changed clinical management of metastatic urothelial carcinoma and metastatic renal cell carcinoma. However, response rates are low, and bio...

    Authors: Jason Zhu, Andrew J. Armstrong, Terence W. Friedlander, Won Kim, Sumanta K. Pal, Daniel J. George and Tian Zhang

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:4

    Published on:

  18. Content type: Review

    Early preclinical evidence provided the rationale for programmed cell death 1 (PD-1) and programmed death ligand 1 (PD-L1) blockade as a potential form of cancer immunotherapy given that activation of the PD-1...

    Authors: Jun Gong, Alexander Chehrazi-Raffle, Srikanth Reddi and Ravi Salgia

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:8

    Published on:

  19. Content type: Research article

    An elevated Neutrophil-to-lymphocyte ratio (NLR) is associated with worse outcomes in several malignancies. However, its role with contemporary immune checkpoint blockade (ICB) is unknown. We investigated the ...

    Authors: Aly-Khan A. Lalani, Wanling Xie, Dylan J. Martini, John A. Steinharter, Craig K. Norton, Katherine M. Krajewski, Audrey Duquette, Dominick Bossé, Joaquim Bellmunt, Eliezer M. Van Allen, Bradley A. McGregor, Chad J. Creighton, Lauren C. Harshman and Toni K. Choueiri

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:5

    Published on:

  20. Content type: Short report

    Merkel cell carcinoma (MCC) is a rare, aggressive skin cancer associated with poor survival outcomes in patients with distant metastatic disease (mMCC). In an initial analysis from JAVELIN Merkel 200, a phase ...

    Authors: Howard L. Kaufman, Jeffery S. Russell, Omid Hamid, Shailender Bhatia, Patrick Terheyden, Sandra P. D’Angelo, Kent C. Shih, Céleste Lebbé, Michele Milella, Isaac Brownell, Karl D. Lewis, Jochen H. Lorch, Anja von Heydebreck, Meliessa Hennessy and Paul Nghiem

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:7

    Published on:

  21. Content type: Case report

    The assessment of tumor size by RECIST using CT scans and MRIs is considered to be standard of care for staging cancer patients. Despite radiologic evidence of widespread disease, we document for the first tim...

    Authors: Stefan Schliep, Abbas Agaimy, Alexander Cavallaro, Franklin Kiesewetter, Gerold Schuler and Lucie Heinzerling

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:2

    Published on:

  22. Content type: Case report

    Cytokine release syndrome (CRS) has been reported after immunologic manipulations, most often through therapeutic monoclonal antibodies. To our knowledge, CRS after radiation therapy (RT) for cancer has not be...

    Authors: Christopher A. Barker, Samuel K. Kim, Sadna Budhu, Konstantina Matsoukas, Anthony F. Daniyan and Sandra P. D’Angelo

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:1

    Published on:

  23. Content type: Research article

    Immunotherapies, specifically those based on immune checkpoint inhibitors, have shown promising activity in multiple tumor types. Other than mifamurtide (MEPACT®) for osteosarcoma approved by European Medicine...

    Authors: Roman Groisberg, David S. Hong, Amini Behrang, Kenneth Hess, Filip Janku, Sarina Piha-Paul, Aung Naing, Siqing Fu, Robert Benjamin, Shreyaskumar Patel, Neeta Somaiah, Anthony Conley, Funda Meric-Bernstam and Vivek Subbiah

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:100

    Published on:

  24. Content type: Commentary

    Commentary on « Cerebral vasculitis mimicking intracranial metastatic progression of lung cancer during PD-1 blockade » by Läubli H et al., J Immunother Cancer. 2017;5:46.

    Authors: Roger Sun, Francois-Xavier Danlos, Samy Ammari, Guillaume Louvel, Frédéric Dhermain, Stéphane Champiat, Olivier Lambotte and Eric Deutsch

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:96

    Published on:

Previous Page Page 1 of 61 Next Page

2016 Journal Metrics